Drug Profile

JY 208

Alternative Names: JY-208

Latest Information Update: 01 Dec 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shenzhen Enduring Biotech
Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunoglobulin Fv fragments; Polyethylene glycols; Recombinant fusion proteins
Mechanism of Action Cell death stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

23 Nov 2022 Preclinical trials in Solid tumours in China (Parenteral) prior to November 2022 (Shenzhen Enduring Biotech pipeline; November 2022)
20 Jul 2021 Shenzhen Enduring Biotech has patent protection for its core technology platform in USA (Shenzhen Enduring Biotech website; November 2022).
15 Apr 2021 Shenzhen Enduring Biotech files a PCT application for Antibody drug conjugate worldwide

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com